Clinicians should remain vigilant for the possibility of MPA in patients exhibiting interstitial pneumonia, recurrent heart failure, bilateral pleural effusion, positive MPO-ANCA, and inadequate responses to anti-heart failure or anti-infective therapies, and should consider initiating appropriate treatment for vasculitis in such cases. The gene discussed is MPO; the disease is Pleural effusion.